7-ethoxyquinoline-3-carbaldehyde

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-ethoxyquinoline-3-carbaldehyde
• 化学式: C₁₂H₁₁NO₂
• 分子量: 201.225
• InChiKey: BAUQSXNPDVKKHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-ethoxyquinoline-3-carbaldehyde 在 N-溴代丁二酰亚胺(NBS) 、 sodium hydride 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.66h， 生成 5-amino-3-(7-ethoxyquinolin-3-yl)-1-(4-hydroxybutan-2-yl)-1H-pyrazole-4-carboxamide
  参考文献：
  名称：

  SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1

  摘要：

  We previously discovered compounds based on a 5-aminopyrazole-4-carboxamide scaffold to be potent and selective inhibitors of CDPK1 from T. gondii. The current work, through structure-activity relationship studies, led to the discovery of compounds (34 and 35) with improved characteristics over the starting inhibitor 1 in terms of solubility, plasma exposure after oral administration in mice, or efficacy on parasite growth inhibition. Compounds 34 and 35 were further demonstrated to be more effective than 1 in a mouse infection model and markedly reduced the amount of T. gondii in the brain, spleen, and peritoneal fluid, and 35 given at 20 mg/kg eliminated T. gondii from the peritoneal fluid.

  DOI：

  10.1021/acsmedchemlett.5b00319
• 作为产物：
  描述：

  3-乙氧基乙酰苯胺 在 四(三苯基膦)钯 、 甲酸 、 三乙胺 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 7-ethoxyquinoline-3-carbaldehyde
  参考文献：
  名称：

  Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy

  摘要：

  Cryptosporidium is a leading cause of pediatric diarrhea worldwide. Currently, there is neither a vaccine nor a consistently effective drug available for this disease. Selective 5-aminopyrazole-4-carboxamide-based bumped-kinase inhibitors (BKIs) are effective in both in vitro and in vivo models of Cryptosporidium parvum. Potential cardiotoxicity in some BKIs led to the continued exploration of the 5-aminopyrazole-4-carboxamide scaffold to find safe and effective drug candidates for Cryptosporidium. A series of newly designed BKIs were tested for efficacy against C. parvum using in vitro and in vivo (mouse infection model) assays and safety issues. Compound 6 (BKI 1708) was found to be efficacious at 8 mg/kg dosed once daily (QD) for 5 days with no observable signs of toxicity up to 200 mg/kg dosed QD for 7 days. Compound 15 (BKI 1770) was found to be efficacious at 30 mg/kg dosed twice daily (BID) for 5 days with no observable signs of toxicity up to 300 mg/kg dosed QD for 7 days. Compounds 6 and 15 are promising preclinical leads for cryptosporidiosis therapy with acceptable safety parameters and efficacy in the mouse model of cryptosporidiosis.

  DOI：

  10.1021/acs.jmedchem.9b00069

文献信息

• SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A)
  申请人：Leblond Bertrand

  公开号：US20120214837A1

  公开（公告）日：2012-08-23

  The invention relates to compounds of the formula wherein R′, R 1 , through R 7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.

  本发明涉及具有以下公式的化合物 其中R'，R1，到R7和Ar如本文所述定义。这些化合物作为磷酸二酯酶10（PDE10A）的抑制剂，可用于治疗中枢神经系统疾病，如精神疾病，也可用于治疗例如肥胖、2型糖尿病、代谢综合征、葡萄糖不耐受、疼痛和眼科疾病。
• Enantioselective Synthesis of Substituted 3-Quinolyl Alkanols and Their Application to Asymmetric Autocatalysis
  作者：Kenso Soai、Itaru Sato、Tomohiko Nakao、Rie Sugie、Tsuneomi Kawasaki

  DOI：10.1055/s-2004-822402

  日期：——

  Enantioenriched 3-quinolyl alkanols act as asymmetric autocatalysts in the addition of diisopropylzinc to the corresponding substituted quinoline-3-carbaldehydes, to afford themselves with an amplified enantiomeric excess(ee) of up to 97%.

  对映体富集的 3-喹啉链烷醇在将二异丙基锌添加到相应的取代的 quinoline-3-carbaldehydes 时充当不对称自催化剂，使其自身具有高达 97% 的放大对映体过量 (ee)。
• [EN] 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM<br/>[FR] INHIBITEURS 5-AMINOPYRAZOLE-4-CARBOXAMIDE DE CDPK1 ISSUES DE T. GONDII ET C. PARVUM
  申请人：UNIV WASHINGTON CT COMMERCIALI

  公开号：WO2014189947A1

  公开（公告）日：2014-11-27

  The present disclosure is generally directed to compositions and methods for treating apicomplexan protozoan related disease, such as toxoplasmosis and cryptosporidiosis.

  本公开通常涉及用于治疗顶复门原虫相关疾病的组合物和方法，例如弓形虫病和隐孢子虫病。
• SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A)
  申请人：Allergan, Inc.

  公开号：US20140309253A1

  公开（公告）日：2014-10-16

  The invention relates to compounds of the formula wherein R′, R 1 through R 7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.

  本发明涉及以下式子中的化合物，其中R′、R1至R7和Ar如本文所定义。这些化合物可用作磷酸二酯酶10（PDE10A）的抑制剂，对于治疗中枢神经系统疾病如精神病以及治疗肥胖症、2型糖尿病、代谢综合征、葡萄糖不耐受、疼痛和眼科疾病等方面非常有用。
• Potent and Selective Inhibitors of CDPK1 from <i>T. gondii</i> and <i>C. parvum</i> Based on a 5-Aminopyrazole-4-carboxamide Scaffold
  作者：Zhongsheng Zhang、Kayode K. Ojo、RamaSubbaRao Vidadala、Wenlin Huang、Jennifer A. Geiger、Suzanne Scheele、Ryan Choi、Molly C. Reid、Katelyn R. Keyloun、Kasey Rivas、Latha Kallur Siddaramaiah、Kenneth M. Comess、Kenneth P. Robinson、Philip J. Merta、Lemma Kifle、Wim G. J. Hol、Marilyn Parsons、Ethan A. Merritt、Dustin J. Maly、Christophe L. M. J. Verlinde、Wesley C. Van Voorhis、Erkang Fan

  DOI：10.1021/ml400315s

  日期：2014.1.9

  5-Aminopyrazole-4-carboxamide was used as an alternative scaffold to substitute for the pyrazolopyrimidine of a known "bumped kinase inhibitor" to create selective inhibitors of calcium-dependent protein kinase-1 from both Toxoplasma gondii and Cryptosporidium parvum. Compounds with low nanomolar inhibitory potencies against the target enzymes were obtained. The most selective inhibitors also exhibited submicromolar activities in T. gondii cell proliferation assays and were shown to be non-toxic to mammalian cells.